Novel H1N1 (Swine Flu) FAQ
Q. What are the plans for developing novel H1N1 vaccine?
Vaccines are the most powerful public health tool for control of
influenza, and the U.S. government is working closely with manufacturers
to take steps in the process to manufacture a novel H1N1 vaccine.
Working together with scientists in the public and private sector, CDC
has isolated the new H1N1 virus and modified the virus so that it can be
used to make hundreds of millions of doses of vaccine. Vaccine
manufacturers are now using these materials to begin vaccine production.
Making vaccine is a multi-step process which takes several months to
complete. Candidate vaccines will be tested in clinical trials over the
Q. When is it expected that the novel H1N1 vaccine will be available?
The novel H1N1 vaccine is expected to be available in the fall. More
specific dates cannot be provided at this time as vaccine availability
depends on several factors including manufacturing time and time needed
to conduct clinical trials
Q. Will the seasonal flu vaccine also protect against the novel H1N1 flu?
A. The seasonal flu vaccine is not expected to protect against the novel H1N1 flu.
Q. Can the seasonal vaccine and the novel H1N1 vaccine be given at the same time?
It is anticipated that seasonal flu and novel H1N1 vaccines may be
administered on the same day. However, we expect the seasonal vaccine to
be available earlier than the H1N1 vaccine. The usual seasonal
influenza viruses are still expected to cause illness this fall and
winter. Individuals are encouraged to get their seasonal flu vaccine as
soon as it is available.
Q. Who will be recommended as priority groups to receive the novel H1N1 vaccine?
CDC's Advisory Committee on Immunization Practices (ACIP) has
recommended that certain groups of the population receive the novel H1N1
vaccine when it first becomes available. These key populations include
pregnant women, people who live with or care for children younger than 6
months of age, healthcare and emergency medical services personnel,
persons between the ages of 6 months and 24 years old, and people ages
of 25 through 64 years of age who are at higher risk for novel H1N1
because of chronic health disorders or compromised immune systems.
do not expect that there will be a shortage of novel H1N1 vaccine, but
availability and demand can be unpredictable. There is some possibility
that initially the vaccine will be available in limited quantities. In
this setting, the committee recommended that the following groups
receive the vaccine before others: pregnant women, people who live with
or care for children younger than 6 months of age, health care and
emergency services personnel with direct patient contact, children 6
months through 4 years of age, and children 5 through 18 years of age
who have chronic medical conditions.
committee recognized the need to assess supply and demand issues at the
local level. The committee further recommended that once the demand for
vaccine for these prioritized groups has been met at the local level,
programs and providers should begin vaccinating everyone from ages 25
through 64 years. Current studies indicate the risk for infection among
persons age 65 or older is less than the risk for younger age groups.
Therefore, as vaccine supply and demand for vaccine among younger age
groups is being met, programs and providers should offer vaccination to
people over the age of 65.
Q. Where will the vaccine be available?
Every state is developing a vaccine delivery plan. Vaccine will be
available in a combination of settings such as vaccination clinics
organized by local health departments, healthcare provider offices,
schools, and other private settings, such as pharmacies and workplaces.
Q. Are there other ways to prevent the spread of illness?
A. Take everyday actions to stay healthy.
- Cover your nose and mouth with a tissue when you cough or sneeze. Throw the tissue in the trash after you use it.
your hands often with soap and water, especially after you cough or
sneeze. Alcohol-based hands cleaners are also effective.
- Avoid touching your eyes, nose or mouth. Germs spread that way.
home if you get sick. CDC recommends that you stay home from work or
school and limit contact with others to keep from infecting them.
public health advice regarding school closures, avoiding crowds and
other social distancing measures. These measures will continue to be
important after a novel H1N1 vaccine is available because they can
prevent the spread of other viruses that cause respiratory infections.
Q. What about the use of antivirals to treat novel H1N1 infection?
Antiviral drugs are prescription medicines (pills, liquid or an inhaled
powder) that fight against the flu by keeping flu viruses from
reproducing in your body. If you get sick, antiviral drugs can make your
illness milder and make you feel better faster. They may also prevent
serious flu complications. This fall, antivirals may be prioritized for
persons with severe illness or those at higher risk for flu
Q. Will vaccination against the new H1N1 influenza be mandatory?
CDC and ACIP (The Advisory Committee on Immunization Practices, which
provides advice and guidance on the control of vaccine-preventable
diseases) will make recommendations for who should receive H1N1 vaccine,
and state and local health departments and institutions will determine
how to implement these recommendations. If the vaccine is recommended
for use, those who choose vaccination for themselves or their children
will be screened for contraindications to vaccination (such as an
allergy to eggs ) and will receive information sheets describing the
vaccine's risks and benefits, possible adverse events associated with
vaccination, and how to report these events.